https://www.selleckchem.com/products/sm-164.html
Colorectal cancer (CRC) is the third leading cause of cancer death worldwide, and its incidence is steadily rising in developing nations. Cell cycle aberrations due to deregulation of cyclin dependent kinases (CDKs) and cyclins are common events during colorectal carcinogenesis. Yet, efficacy of multitarget CDK inhibitors as therapeutic agents has not been much explored against CRC. The anticancer potential of multitarget CDK inhibitor riviciclib (also known as P276-0, was investigated against CRC cell lines of varied genetic backgroun
Like
Comment
Share
